Lacnotuzumab (MCS110, Novartis) completed a Phase 2 trials to evaluate the safety, tolerability, and effectiveness of Lacnotuzumab in 36 patients with diffuse TGCT. Lacnotuzumab was administered as a single dose of 10 mg/kg or multiple doses of 3 mg/kg, 5 mg/kg or 10 mg/kg. Results suggest that after a single dose, the tumor size was reduced by 33% after 10 mg/kg (1). At the end of treatment, the lowest dose of 3 mg/kg led to 30% reduction in tumor volume, the medium dose of 5 mg/kg led to 56% tumor reduction, and the highest dose of 10 mg/kg led to tumor size reduction of 55%, however, side effects also increased following 10 mg/kg. The study completed in 2018.
While both Vimseltinib and Pexidartinib are molecule-based drugs (like many oral pills on market), this drug relies on a protein antibody that blocks CSF1 by holding onto it and preventing it from reaching TGCT and surrounding cells. This drug was given as an intravenous infusion. Side effects include changes in liver enzymes, swelling of the face and eyes, and elevation in an enzyme called creatinine kinase.
By blocking CSF1, the tumor cannot grow and develop. This clinical trial took place at 8 different clinical locations.
For more information, visit the Clinical Trial site for MCS110or ask your healthcare provider. As of 2021, it is unknown whether this drug will continue.
